Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

270.04 +4.23 (+1.59%)
Streaming Delayed Price Updated: 2:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Why ZoomInfo (GTM) Stock Is Nosediving
What Happened? Shares of go-to-market intelligence provider ZoomInfo (NASDAQ:GTM) fell 11.1% in the afternoon session after the company faced continued fallo... 
Via StockStory
Topics Artificial Intelligence Government
News headline image
Primerica (PRI) Q1 2026 Earnings Transcript ↗
Primerica (PRI) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
3 Stocks I’d Use to Build a Smart TFSA Portfolio in 2026 ↗
Three stocks that offer a blend of safety, growth and yield are a smart way to build a TFSA portfolio in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 Canadian Stock Ready to Rise in 2026 ↗
A hybrid utility stock and energy exporter stands ready to rise further in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
An Ideal TFSA Stock With a Steady 4.7% Yield ↗
A top Canadian REIT with a proven dividend track record and steady yield is an ideal holding in a TFSA. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Are Asana (ASAN) Shares Soaring Today
What Happened? Shares of work management platform Asana (NYSE:ASAN) jumped 12.7% in the afternoon session after the company reported an impressive “beat and ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Ferrari Launches Most Polarizing Vehicle in History -- It's Time to Buy the Stock ↗
Ferrari is again zigging when rivals zag, and unveiled its first full-electric vehicle recently -- but will the gamble reward investors? 
Via The Motley Fool
News headline image
Is GE Aerospace Stock Outperforming the S&P 500?
Having outpaced the S&P 500 Index over the past year, GE Aerospace continues to garner strong analyst support. 
Via Barchart.com
Topics Stocks
News headline image
Prediction: The Pullback in This Canadian Bank Stock Is a Buying Opportunity ↗
RBC doesn’t need a perfect economy to reward long-term investors – it needs a fear-driven dip that doesn’t break its fundamentals. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
RBC Just Upped Its Price Target on Marvell Technology Stock. Here's Why
Marvell stock gains as robust Q1 earnings makes RBC raise its price target to $240. Here’s why the investment firm is bullish on MRVL shares. 
Via Barchart.com
Topics Artificial Intelligence Supply Chain
News headline image
Why Veeva Systems (VEEV) Stock Is Up Today
What Happened? Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 3.8% in the afternoon session after the company announced tha... 
Via StockStory
Topics Artificial Intelligence
News headline image
Royal Bank Of Canada Q2 Earnings Call Highlights ↗
Royal Bank Of Canada (NYSE:RY) reported fiscal second-quarter earnings of CAD 5.5 billion, with adjusted earnings of CAD 5.6 billion, as management highlighted strong results across capital markets,... 
Via MarketBeat
Topics Earnings World Trade
News headline image
Are Wall Street Analysts Predicting FactSet Research Systems Stock Will Climb or Sink?
As FactSet Research Systems has notably lagged the broader market over the past 52 weeks, Wall Street analysts maintain a cautious outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs Supply Chain
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
Via MarketBeat
News headline image
M&T Bank Stock: Is Wall Street Bullish or Bearish?
M&T Bank has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data ↗
Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while... 
Via MarketBeat
News headline image
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst ↗
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within... 
Via MarketBeat
News headline image
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare... 
Via MarketBeat
News headline image
A Canadian Energy Stock Ready to Bring in the Heat in 2026 ↗
Cenovus Energy is a strong buy in 2026 for its massive free cash flow and refining power. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Best Canadian Stocks to Own During a Trade War ↗
Three Canadian stocks are the top buys for investors seeking built-in defences during a trade war. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
News headline image
Do Wall Street Analysts Like Air Products and Chemicals Stock?
Despite Air Products and Chemicals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs Supply Chain
News headline image
3 Market-Beating Stocks on Our Watchlist
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Stocks That Could Turn $100,000 Into $1 Million ↗
Two stocks and an income-and-growth strategy could turn $100,000 into a seven-figure fortune over time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC... 
Via MarketBeat
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president... 
Via MarketBeat
News headline image
A Perfect TFSA Pair for 2026: 2 Stocks I’d Buy Now ↗
Royal Bank of Canada (TSX:RY) and another great pick for a TFSA fund. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗
Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS... 
Via MarketBeat
News headline image
Are Wall Street Analysts Predicting Cboe Global Markets Stock Will Climb or Sink?
Cboe Global Markets has considerably outperformed the broader market over the past 52 weeks, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects. 
Via Barchart.com
Topics Derivatives ETFs
News headline image
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent... 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.